2014 Clinical Trials Methodology Course presentation on NeuroNEXT
External Source:
Chris Coffey and Laurie Gutmann presented at the 2014 NINDS-funded Clinical Trials Methodology Course.
NN101 SMA poster presented at Families of SMA annual meeting
View the 
poster presented at the 2013 Families of SMA Annual Meeting by the NN101 SMA team.
NeuroNEXT praised as "a burst of speed for neurological research"
External Source:
The August 2013 issue of Annals of Neurology describes how NeuroNEXT can streamline neurological research.
President of the Child Neurology Society describes next generation of neurological research
In a January/February 2013 editorial, the president of the Child Neurology Society praises the formation of the NeuroNEXT Network and the possibility for it to rapidly evaluate new treatments for neurological disorders.
Steve Kolb explains NN101-SMA
External Source:
View Steve Kolb's video announcement of the NN101 SMA study.
February 2012 issue of The Lancet Neurology praises formation of NeuroNEXT
External Source:
Article Summary: In February, 2012, the US National Institute for Neurological Disorders and Stroke (NINDS) is due to announce the first study to be supported by the National Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). With this ambitious new network, NINDS aims to facilitate the progress of new drugs from the laboratory to the clinic, specifically at the stage of phase 2 trials and biomarker validation studies. New therapies for neurological diseases are undoubtedly needed, but how can NeuroNEXT make a difference?
NeuroNEXT U01 funding announcement
Please visit the NIH page for information related to the NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) funding mechanism. The FOA is available for applications beginning January 5, 2018, through January 8, 2021.
- « first
- ‹ previous
- 1
- 2
- 3